Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 12- to 15-month-old males and females with no active liver disease~* A negative history of hepatitis A, measles, mumps, rubella, chickenpox, and/or zoster~Exclusion Criteria:~* Males and females previously vaccinated with hepatitis A, measles, mumps, rubella, and/or chickenpox vaccine~* Any immune deficiency~* History of allergy to any of the vaccine components~* History of any seizure disorder

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 15 Months
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Arm 1: VAQTA™ 0.5 mL injection (2 doses 6 months apart), ProQuad™ 0.5 mL injection (2 doses 6 months apart), Prevnar™ 0.5 mL injection (one dose), all vaccines administered concomitantly. 28 weeks of study duration.
- 2 (Type: ACTIVE_COMPARATOR): Arm 2: ProQuad™ 0.5 mL injection (2 doses \~8 months apart), Prevnar™ 0.5 mL injection (one dose), both administered concomitantly, VAQTA™ 0.5 mL injection (2 doses 6 months apart) administered alone. 34 weeks of study duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).